Holly D. Maples
Professor
Also affiliated: Eugene Applebaum College of Pharmacy and Health Sciences (2020); Arkansas Children's Hospital (2003–2025); Children's Hospital of Philadelphia (2024); Wayne State University (2020); University of Arkansas Medical Center (2025); Albany College of Pharmacy and Health Sciences (2020)
Pharmacy Practice, College of Pharmacy
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Holly D. Maples, a Professor in Pharmacy Practice at the University of Arkansas for Medical Sciences College of Pharmacy, focuses her research on antimicrobial stewardship and therapeutic drug monitoring, particularly for serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Her work has contributed to revised consensus guidelines for vancomycin therapy, developed in collaboration with major professional societies. Maples also investigates patterns of hospital antibiotic use, including analyses of pediatric data from a global perspective, and examines antimicrobial stewardship strategies specifically within pediatric populations. Her scholarship includes 54 publications, with an h-index of 19, and she has been recognized as a highly cited researcher. She frequently collaborates with colleagues at the University of Arkansas for Medical Sciences, including Adriana Sarmiento Clemente and Steven Dahl, on shared publications.
Metrics
- h-index: 19
- Publications: 54
- Citations: 2,961
Positions
-
Director of Impact and Postgradaute Research 2020–presentUniversity of Essex East 15 ORCID
-
Professor publications 2003–2025University of Arkansas for Medical Sciences Pharmacy Practice, College of Pharmacy Institutional directory
-
Senior Lecturer in Theatre 2014–2019Brunel University London College of Business, Art, and Humanities ORCID
-
Lecturer in Theatre 2007–2014University of East Anglia Literature, Drama, and Creative Writing ORCID
Selected Publications
-
Optimizing Antibiotic Duration for Acute Otitis Media: A Tale of Two Pediatric Emergency Departments (2026)
-
Impact of Reflex Urine Culture Algorithm in a Pediatric Emergency Department (2026)
-
Evaluation and treatment of infective endocarditis in children and adolescents with underlying CHD: a Paediatric Acute Care Cardiology Collaborative Clinical Practice Guideline (2025)
-
Evaluating the Impact of Handshake Rounds on Antibiotic Prescribing in Children Diagnosed With Community Acquired Pneumonia (2025)
-
Measurement of Practice-Level Antibiotic Utilization in a Medicaid Patient-Centered Medical Home Program (2025)
-
Identifying Disparities in Outpatient Antibiotic Prescribing for Urinary Tract Infections (2024)
-
Evaluating the Impact of Order Set Implementation in Prescribing Practices for Pediatric Urinary Tract Infections Between a Non-academic and an Academic Children’s Hospital in the Inpatient General Pediatric Population (2024)
-
The Impact of a UTI Pathway Bundle on Antibiotic Prescribing for Pediatric Urinary Tract Infections Through the Lens of Health Equity in Two Emergency Departments within a Children’s Hospital System (2024)
-
Assessment of Broad-Spectrum Antibiotic Usage Following Initiation of Handshake Stewardship in a Pediatric Intensive Care Unit: A Quality Improvement Initiative (2024)
-
Feasibility and Prevalence of Early Antibiotic De-Escalation in Patients with Viral Encephalitis (2024)
-
1710. Clostridioides difficile Bundle Implementation Reduces Unnecessary Testing in Pediatric Patients (2023)
-
Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia (2023)
-
933. Antibiotic Prescribing Changes in Adults During COVID-19 in Outpatient Patient-Centered Medical Homes (PCMH) in Arkansas (2022)
-
Antimicrobial Stewardship in Cystic Fibrosis (2022)
-
Lactococcus Species Central Line-Associated Bloodstream Infection in Pediatrics: A Case Series (2022)
Collaboration Network
Top Collaborators
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Showing 5 of 6 shared publications
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- Questions on Vancomycin Dosing
- Evaluating the Impact of Order Set Implementation in Prescribing Practices for Pediatric Urinary Tract Infections Between a Non-academic and an Academic Children’s Hospital in the Inpatient General Pediatric Population
- Feasibility and Prevalence of Early Antibiotic De-Escalation in Patients with Viral Encephalitis
- Assessment of Broad-Spectrum Antibiotic Usage Following Initiation of Handshake Stewardship in a Pediatric Intensive Care Unit: A Quality Improvement Initiative
- Identifying Disparities in Outpatient Antibiotic Prescribing for Urinary Tract Infections
- Evaluating the Impact of Handshake Rounds on Antibiotic Prescribing in Children Diagnosed With Community Acquired Pneumonia
- Evaluating the Impact of Order Set Implementation in Prescribing Practices for Pediatric Urinary Tract Infections Between a Non-academic and an Academic Children’s Hospital in the Inpatient General Pediatric Population
- Feasibility and Prevalence of Early Antibiotic De-Escalation in Patients with Viral Encephalitis
- Assessment of Broad-Spectrum Antibiotic Usage Following Initiation of Handshake Stewardship in a Pediatric Intensive Care Unit: A Quality Improvement Initiative
- Identifying Disparities in Outpatient Antibiotic Prescribing for Urinary Tract Infections
- Evaluating the Impact of Handshake Rounds on Antibiotic Prescribing in Children Diagnosed With Community Acquired Pneumonia
- Evaluating the Impact of Order Set Implementation in Prescribing Practices for Pediatric Urinary Tract Infections Between a Non-academic and an Academic Children’s Hospital in the Inpatient General Pediatric Population
- Feasibility and Prevalence of Early Antibiotic De-Escalation in Patients with Viral Encephalitis
- Assessment of Broad-Spectrum Antibiotic Usage Following Initiation of Handshake Stewardship in a Pediatric Intensive Care Unit: A Quality Improvement Initiative
- Identifying Disparities in Outpatient Antibiotic Prescribing for Urinary Tract Infections
- Optimizing Antibiotic Duration for Acute Otitis Media: A Tale of Two Pediatric Emergency Departments
- Intravenous Voriconazole Therapy in a Preterm Infant
- Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection
- Famotidine Disposition in Children and Adolescents with Chronic Renal Insufficiency
- 215 EVALUATION OF SHORT COURSE DIRECT OBSERVATIONAL THERAPY IN PEDIATRIC HIV PATIENTS.
- Antimicrobial Stewardship in Pediatrics
- Finding the relevance of antimicrobial stewardship for cystic fibrosis
- Expanding Existing Antimicrobial Stewardship Programs in Pediatrics: What Comes Next
- Antimicrobial Stewardship in Cystic Fibrosis
Similar Researchers
Based on overlapping research topics